SELLAS shares jump 157% after company says its leukemia
SELLAS Life Sciences (SLS) shares surged 157% after reporting positive Phase 3 trial results for its leukemia vaccine, galinpepimut-S, showing a 41% reduction in death risk. The stock closed at $19.17, valuing the company at $3.9B. However, after launching a $150M stock offering, shares dropped 10-13% in after-hours trading. The trial enrolled 126 patients, with median survival of 24.0 months vs. 14.7 months for existing treatments. The company plans to file for regulatory approval in 2027.
How this was made
The 30-second read
Why it matters
The Phase 3 survival readout is the primary catalyst for the outsized rally, but the concurrent equity sale introduces dilution and liquidity overhang, producing after-hours drawdown and likely continued volatility until offering details and subsequent clinical/filing milestones clarify value.
Market read
Traders must weigh a headline-positive Phase 3 survival result against immediate dilution from a same-day equity offering, which the article links to after-hours weakness.
What to watch
The article notes no peer review and missing confidence intervals, plus uncertainty around post-trial therapies and secondary endpoint timing, which can drive rapid sentiment reversals after the initial headline spike.
Background
SELLAS (SLS) announced Phase 3 REGAL topline results for its leukemia vaccine galinpepimut-S (GPS) in acute myeloid leukemia, then launched a $150 million underwritten stock offering the same day.
Ticker impact
SELLAS reported Phase 3 REGAL results for galinpepimut-S, cutting death risk by 41% (HR 0.59, p=0.035), triggering a 156.6% one-day jump and a same-day $150M offering.
Shares likely face two-way volatility, with initial biotech-readthrough support offset by sell-side pressure from the concurrent equity offering.
The article ties the surge to the Phase 3 survival readout, then notes after-hours weakness following the $150M offering, implying the market is balancing efficacy optimism against dilution and execution risk.
Market effects
Reinforces high sensitivity of small-cap biotech valuations to Phase 3 topline readouts, while highlighting how immediate equity issuance can cap follow-through.
Limited, primarily affecting US small-cap biotech sentiment rather than broad indices.
Low, as the catalyst is company-specific clinical data and a US equity offering.
Counterpoint
The survival benefit may be overstated versus active comparators because the control arm includes observation, and the trial’s statistical precision is thin without confidence intervals.
Key entities
- companySELLAS
Subject of the article; shares surged after Phase 3 REGAL survival results and then sold off after a same-day $150M offering.
- productgalinpepimut-S (GPS)
Leukemia vaccine evaluated in Phase 3 REGAL; reported to reduce risk of death versus best available treatment.
- clinical_trialREGAL trial
Phase 3 study in AML; reported median overall survival 24.0 months vs 14.7 months, HR 0.59, p=0.035.
- capital_raise$150 million underwritten offering
Same-day equity offering led by J.P. Morgan and TD Cowen, with a 30-day option for additional shares.

